SHR-1210 (tislelizumab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SHR-1210 (tislelizumab), covering 2025-01-03 to 2025-01-03. Get the full timeline:
Most recent: Clinical Trial Update: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery [Phase 2]